Pepcid (Famotidine) Should NOT Be Used to Treat Psoriasis
Pepcid (famotidine) is an H2-receptor antagonist FDA-approved only as an acid reducer for heartburn and acid indigestion, and has no established role in psoriasis treatment. 1
Why This Is Not a Treatment Option
The FDA labeling for Pepcid makes no mention of psoriasis or any dermatologic indication 1. The established treatment guidelines for psoriasis from the Joint AAD-NPF Guidelines (2021) provide comprehensive recommendations for both topical and systemic therapies, and famotidine is completely absent from these evidence-based treatment algorithms 2, 3.
What You Should Use Instead
For mild to moderate psoriasis, the guideline-recommended first-line topical treatments include 2:
- Vitamin D analogues (calcipotriene, calcitriol, maxacalcitol) - Grade A recommendation
- Combination calcipotriene plus betamethasone dipropionate - Grade A recommendation
- Topical corticosteroids (medium to high potency) combined with vitamin D analogues for up to 52 weeks - Grade A recommendation
- Tazarotene (topical retinoid) for 8-12 weeks - recommended option
For moderate to severe psoriasis requiring systemic therapy, established options include 3:
- Methotrexate, adalimumab, or ustekinumab as primary systemic treatments
- Cyclosporine for rapid control (though not for long-term use)
- Acitretin, particularly effective for pustular and erythrodermic variants
Important Caveat About H2-Blockers
While one small study from 2000 showed famotidine had some efficacy in acute urticaria (a completely different condition involving histamine-mediated hives) 4, this does not translate to psoriasis treatment. Psoriasis is an immune-mediated inflammatory disease involving T-cell activation and cytokine dysregulation—not a histamine-mediated process.
Additionally, there is concerning evidence that proton pump inhibitors (PPIs, which are related acid-suppressing medications) may actually increase psoriasis risk (adjusted OR 1.52-1.54 for higher cumulative doses) 5. While this study examined PPIs rather than H2-blockers like famotidine, it raises questions about whether acid-suppressing medications as a class might negatively impact psoriasis.
The Bottom Line Algorithm
- For new psoriasis diagnosis: Start with topical vitamin D analogue + corticosteroid combination products
- For inadequate response to topicals or BSA >10%: Transition to systemic therapy (methotrexate, biologics, or other guideline-recommended agents)
- Never use famotidine for psoriasis—it lacks efficacy data, FDA approval, and guideline support for this indication